The Chinese MOFCOM imposes conditions on merger in pharmaceutical industry (Novartis / Alcon)

After a four-month review, on 13 August 2010, China's Ministry of Commerce (“MOFCOM”) authorized Novartis‘ acquisition of Alcon subject to conditions. Taking different approaches than one would see in the U.S. or European Union, MOFCOM's decision is notable for the demanding view it takes of transactions involving a combination of large and small market shares and for the nature of the remedy imposed. I. Background This is MOFCOM's seventh published merger control decision under the Anti-Monopoly Law “AML”). These include six conditional approvals and one prohibition (Coca Cola/Huiyuan). MOFCOM is required to publish only rejection or conditional approval decisions, and it has reviewed many transactions beyond these seven. The decision was announced the day after MOFCOM held a press

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Peter J. Wang, Sébastien J. Evrard, Yizhe Zhang, H. Stephen Harris, The Chinese MOFCOM imposes conditions on merger in pharmaceutical industry (Novartis / Alcon), 13 August 2010, e-Competitions Bulletin Exclusive distribution, Art. N° 33660

Visites 1879

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues